HONG KONG – South Korean biotech Bioleaders Co. Ltd., headquartered in Yong-in city, Gyeonggi-do, and Israel's Weizmann Institute of Science, based in Rehovot, recently founded a joint venture in Israel. With the new entity, they will accelerate the R&D of a Weizmann-developed approach targeting p53, a strong tumor suppressor that has proved difficult to drug.

HONG KONG –South Korea's leading biopharmaceutical developer, Celltrion Inc., has launched its early/metastatic breast and gastric cancer biosimilar Herzuma (trastuzumab) in Iraq. It is Herzuma's first foray into the Middle Eastern region.

HONG KONG – Dreamed Diabetes Ltd., of Petah Tikva, Israel, has received both FDA clearance and the CE mark for an insulin dosing decision support software based on artificial intelligence (AI).

TEL AVIV, Israel – Generating all kinds of data that can feed artificial intelligence (AI) and machine learning engines is increasingly cheap and, in many ways, easy but interpreting all that data and translating it into information that is useful to users that range from drug developers to patients remains a significant challenge. Addressing this challenge has blurred the boundaries between traditional technology companies and medical technology companies and forced a rethinking of how treatments are provided, and drugs are developed. And the challenge also creates opportunities for companies that can address this gap.